586 related articles for article (PubMed ID: 18517082)
1. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
Pokladnikova J; Krcmova I; Vlcek J
Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.
Brüggenjürgen B; Reinhold T; Brehler R; Laake E; Wiese G; Machate U; Willich SN
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):316-24. PubMed ID: 18814456
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.
Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB
Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225
[TBL] [Abstract][Full Text] [Related]
4. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland.
Brüggenjürgen B; Reinhold T
J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
7. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma.
Berto P; Bassi M; Incorvaia C; Frati F; Puccinelli P; Giaquinto C; Cantarutti L; Ortolani C
Eur Ann Allergy Clin Immunol; 2005 Oct; 37(8):303-8. PubMed ID: 17066648
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study.
Mauro M; Russello M; Incorvaia C; Gazzola GB; Di Cara G; Frati F
Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):119-22. PubMed ID: 17523385
[TBL] [Abstract][Full Text] [Related]
11. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
[TBL] [Abstract][Full Text] [Related]
12. Economic aspects of sublingual immunotherapy.
Incorvaia C; Ariano R; Berto P; Ciprandi G; Leo G; Boccardo R; Scurati S; Frati F
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):27-30. PubMed ID: 19944007
[TBL] [Abstract][Full Text] [Related]
13. Quality of life outcomes with sublingual immunotherapy.
Wise SK; Woody J; Koepp S; Schlosser RJ
Am J Otolaryngol; 2009; 30(5):305-11. PubMed ID: 19720247
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
15. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.
Nelson H; Cartier S; Allen-Ramey F; Lawton S; Calderon MA
J Allergy Clin Immunol Pract; 2015; 3(2):256-266.e3. PubMed ID: 25609326
[TBL] [Abstract][Full Text] [Related]
16. Rush sublingual immunotherapy in Parietaria allergic patients.
D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis.
Meadows A; Kaambwa B; Novielli N; Huissoon A; Fry-Smith A; Meads C; Barton P; Dretzke J
Health Technol Assess; 2013 Jul; 17(27):vi, xi-xiv, 1-322. PubMed ID: 23827204
[TBL] [Abstract][Full Text] [Related]
19. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
Dranitsaris G; Ellis AK
J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
[TBL] [Abstract][Full Text] [Related]
20. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
